The video features a discussion between Walter Isaacson and Jennifer Doudna, co-author of "Crack in Creation" and a key figure in the development of CRISPR-Cas9 gene editing technology. The conversation explores the science behind CRISPR, its potential applications, and the ethical implications of editing the human genome.
Doudna recounts her early interest in molecular science sparked by James Watson's book "The Double Helix" and her subsequent research on RNA. She explains RNA's crucial role in regulating how genetic information is used in cells, leading to her involvement with CRISPR. She highlights the collaboration with Jill Banfield and Emmanuelle Charpentier, emphasizing that curiosity-driven research and international collaboration are key to scientific breakthroughs.
The discussion delves into the mechanics of CRISPR-Cas9, describing how it acts like "molecular scissors" to precisely cut and paste DNA sequences. Doudna uses the analogy of word processing, emphasizing the technology's accuracy in making targeted genetic changes.
Isaacson and Doudna then explore the implications of gene editing in animals, mentioning examples like pigs engineered for organ donation and mosquitoes modified to resist viruses. They also discussed how China is way ahead of the United States because it's investing more in genetic technology.
The conversation then shifts to the more complex issue of human gene editing, particularly germline editing, which would result in heritable changes passed down to future generations. Doudna emphasizes the difference between somatic cell editing (changes in an individual's cells that aren't passed on) and germline editing, which fundamentally alters the evolution of a species. While she supports somatic cell editing for curing diseases like sickle cell anemia, she expresses caution regarding germline editing, stating that it requires broad societal consensus and more safety data before proceeding.
They then discuss the commercial aspects of CRISPR, discussing a hypothetical story, it shows the challenge society faces when Silicon Valley entrepreneurs want to commercialize genetic engineering. The discussion expands to examine the ethical complexities of gene editing, including modifying the germline. Doudna shares how her own views on germline editing have evolved, influenced by conversations with patients and families facing devastating genetic diseases. She and Isaacson explore potential moral lines, discussing the distinction between correcting diseases and enhancing traits, and how it is up to different jurisdictions to decided. Doudna emphasizes the importance of engaging in international discussions and educating the public about CRISPR's possibilities and challenges.
Finally, Doudna discusses the importance of funding basic scientific research, noting that the CRISPR technology itself emerged from curiosity-driven investigations into bacterial immune systems. She expressed concern that cutting funding for basic research in the U.S. will allow other countries like China to dominate the field. She acknowledged the competitiveness but also the collaboration and fairness with other scientists doing similar work.